{"id":59255,"date":"2026-03-11T14:02:17","date_gmt":"2026-03-11T06:02:17","guid":{"rendered":"https:\/\/flcube.com\/?p=59255"},"modified":"2026-03-11T14:02:18","modified_gmt":"2026-03-11T06:02:18","slug":"fda-accepts-enhertu-sbla-with-priority-review-her2-adc-seeks-early-breast-cancer-approval-with-53-recurrence-risk-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59255","title":{"rendered":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ: AZN<\/a>) and <strong>Daiichi Sankyo<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO: 4568<\/a>) announced that the <strong>U.S. FDA has accepted<\/strong> a <strong>supplemental Biologics License Application (sBLA)<\/strong> for <strong>ENHERTU (trastuzumab deruxtecan)<\/strong> and granted <strong>Priority Review<\/strong> for the treatment of <strong>HER2-positive early breast cancer<\/strong> patients with <strong>residual invasive disease following neoadjuvant HER2-targeted therapy<\/strong>. The filing, supported by <strong>DESTINY-Breast05 Phase III data<\/strong> showing a <strong>53% reduction in invasive disease recurrence or death risk<\/strong> versus T-DM1, positions the <strong>HER2-directed ADC<\/strong> for <strong>curative-intent expansion<\/strong> in the <strong>largest breast cancer segment<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplemental Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td>Priority Review<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ENHERTU (trastuzumab deruxtecan)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>HER2-directed antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>HER2-positive early breast cancer (residual disease post-neoadjuvant therapy)<\/td><\/tr><tr><td><strong>Partners<\/strong><\/td><td>AstraZeneca + Daiichi Sankyo (joint development and commercialization)<\/td><\/tr><tr><td><strong>Supporting Trial<\/strong><\/td><td>DESTINY-Breast05 (Phase III)<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td>[Anticipated Q2 2026 \u2013 Priority Review typically 6 months]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-destiny-breast05-clinical-evidence\">DESTINY-Breast05 Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>ENHERTU<\/th><th>T-DM1 (Comparator)<\/th><th>Clinical Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Invasive Disease-Free Survival (IDFS)<\/strong><\/td><td>92.4%<\/td><td>83.7%<\/td><td><strong>Absolute benefit: 8.7 percentage points<\/strong><\/td><\/tr><tr><td><strong>IDFS Hazard Ratio<\/strong><\/td><td>0.47<\/td><td>Reference<\/td><td><strong>53% reduction in recurrence\/death risk (p&lt;0.0001)<\/strong><\/td><\/tr><tr><td><strong>95% Confidence Interval<\/strong><\/td><td>0.34-0.66<\/td><td>\u2014<\/td><td>Highly statistically significant<\/td><\/tr><tr><td><strong>Subgroup Consistency<\/strong><\/td><td>Benefit across all pre-specified subgroups<\/td><td>\u2014<\/td><td>Broad applicability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Trial Design:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> HER2-positive early breast cancer with residual invasive disease after neoadjuvant HER2-targeted therapy (chemotherapy + trastuzumab \u00b1 pertuzumab)<\/li>\n\n\n\n<li><strong>Setting:<\/strong> Post-neoadjuvant (adjuvant) treatment to eliminate residual disease<\/li>\n\n\n\n<li><strong>Comparator:<\/strong> T-DM1 (ado-trastuzumab emtansine) \u2013 standard of care for residual disease<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Trastuzumab Deruxtecan (ENHERTU) Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Structure<\/strong><\/td><td>HER2 monoclonal antibody + cleavable tetrapeptide linker + topoisomerase I inhibitor payload (DXd)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Targeted delivery of cytotoxic agent to HER2-expressing cells; high payload-to-antibody ratio (DAR ~8); membrane-permeable payload enables bystander effect<\/td><\/tr><tr><td><strong>Approved Indications<\/strong><\/td><td>HER2-positive metastatic breast cancer (2L+); HER2-low metastatic breast cancer; HER2-positive gastric cancer; HER2-mutant NSCLC<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Superior efficacy vs. T-DM1 in metastatic setting; now demonstrating curative-intent benefit in early disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-impact\">Strategic Context &amp; Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Early Breast Cancer Market<\/strong><\/td><td>~60% of HER2+ patients have residual disease post-neoadjuvant; represents largest addressable ENHERTU population to date<\/td><\/tr><tr><td><strong>T-DM1 Displacement<\/strong><\/td><td>DESTINY-Breast05 establishes ENHERTU as new standard of care for residual disease; T-DM1 revenue erosion anticipated<\/td><\/tr><tr><td><strong>Curative Intent<\/strong><\/td><td>Adjuvant approval shifts ENHERTU from palliative to curative positioning; premium pricing justification<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>Analysts project <strong>$5-7 billion incremental annual sales<\/strong> with early breast cancer indication; total ENHERTU franchise approaching <strong>$15 billion peak<\/strong><\/td><\/tr><tr><td><strong>Competitive Moat<\/strong><\/td><td>High barrier to entry for biosimilars\/ADC competitors; DXd payload technology platform protected<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Early Breast Cancer Status<\/th><th>ENHERTU Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Roche<\/strong><\/td><td>Kadcyla (T-DM1)<\/td><td>HER2 ADC (maytansinoid payload)<\/td><td>Approved (residual disease)<\/td><td>Superior IDFS; bystander effect; better tolerability<\/td><\/tr><tr><td><strong>Seagen\/Pfizer<\/strong><\/td><td>Tukysa (tucatinib) + trastuzumab<\/td><td>HER2 TKI + mAb<\/td><td>Approved (adjuvant HER2+)<\/td><td>Oral convenience vs. IV; ENHERTU efficacy advantage in head-to-head<\/td><\/tr><tr><td><strong>AstraZeneca\/Daiichi<\/strong><\/td><td><strong>ENHERTU<\/strong><\/td><td><strong>HER2 ADC (DXd payload)<\/strong><\/td><td><strong>sBLA accepted; Priority Review<\/strong><\/td><td><strong>First ADC with 53% recurrence reduction vs. T-DM1 in early disease<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-commercial-outlook\">Regulatory &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Timeline<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>FDA Priority Review<\/strong><\/td><td>Q2 2026<\/td><td>PDUFA decision anticipated (6-month review)<\/td><\/tr><tr><td><strong>EU EMA Submission<\/strong><\/td><td>2026<\/td><td>sBLA filing expected H1 2026<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>Q3-Q4 2026 (U.S.)<\/td><td>Immediate formulary access given Priority Review; oncology center education<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>2026-2027<\/td><td>Japan, China NDA filings; reimbursement negotiations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FDA approval timelines, commercial launch execution, and competitive positioning for ENHERTU in early breast cancer. Actual results may differ due to regulatory decisions, pricing negotiations, and manufacturing supply constraints.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59256,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,130,770,16,194,871,978],"class_list":["post-59255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-az","tag-cancer","tag-daiichi-sankyo","tag-nasdaq-azn","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59255\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59255\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T06:02:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T06:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction\",\"datePublished\":\"2026-03-11T06:02:17+00:00\",\"dateModified\":\"2026-03-11T06:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255\"},\"wordCount\":572,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1104.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"AZ\",\"Cancer\",\"Daiichi Sankyo\",\"NASDAQ: AZN\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59255#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59255\",\"name\":\"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1104.webp\",\"datePublished\":\"2026-03-11T06:02:17+00:00\",\"dateModified\":\"2026-03-11T06:02:18+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59255\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1104.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59255#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59255","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction","og_description":"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.","og_url":"https:\/\/flcube.com\/?p=59255","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T06:02:17+00:00","article_modified_time":"2026-03-11T06:02:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59255#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59255"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction","datePublished":"2026-03-11T06:02:17+00:00","dateModified":"2026-03-11T06:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59255"},"wordCount":572,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59255#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp","keywords":["ADC \/ XDC","AstraZeneca","AZ","Cancer","Daiichi Sankyo","NASDAQ: AZN","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59255#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59255","url":"https:\/\/flcube.com\/?p=59255","name":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59255#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59255#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp","datePublished":"2026-03-11T06:02:17+00:00","dateModified":"2026-03-11T06:02:18+00:00","description":"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. FDA has accepted a supplemental Biologics License Application (sBLA) for ENHERTU (trastuzumab deruxtecan) and granted Priority Review for the treatment of HER2-positive early breast cancer patients with residual invasive disease following neoadjuvant HER2-targeted therapy. The filing, supported by DESTINY-Breast05 Phase III data showing a 53% reduction in invasive disease recurrence or death risk versus T-DM1, positions the HER2-directed ADC for curative-intent expansion in the largest breast cancer segment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59255#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59255"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59255#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp","width":1080,"height":608,"caption":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59255#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts ENHERTU sBLA with Priority Review \u2013 HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59255"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59255\/revisions"}],"predecessor-version":[{"id":59257,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59255\/revisions\/59257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59256"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}